ScoreWhy is CRISPR Therapeutics AG ?
1
Poor Management Efficiency with a low ROE of 3.15%
- The company has been able to generate a Return on Equity (avg) of 3.15% signifying low profitability per unit of shareholders funds
2
The company has declared Negative results for the last 4 consecutive quarters
- NET SALES(9M) At USD 37.45 MM has Grown at -81.48%
- NET PROFIT(9M) At USD -285.6 MM has Grown at -85.88%
- ROCE(HY) Lowest at -25.34%
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 6.29%, its profits have fallen by -77.6%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is CRISPR Therapeutics AG for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
CRISPR Therapeutics AG
13.54%
-0.17
63.26%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-33.34%
EBIT Growth (5y)
-355.30%
EBIT to Interest (avg)
-271.84
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.08
Tax Ratio
1.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.49%
ROCE (avg)
229.94%
ROE (avg)
3.15%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.98
EV to EBIT
-3.76
EV to EBITDA
-3.91
EV to Capital Employed
-146.84
EV to Sales
47.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-21.08%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
NET SALES(HY)
At USD 1.76 MM has Grown at 72.09%
NET PROFIT(HY)
Higher at USD -248.29 MM
RAW MATERIAL COST(Y)
Fallen by -49.84% (YoY
-12What is not working for the Company
NET SALES(9M)
At USD 37.45 MM has Grown at -81.48%
NET PROFIT(9M)
At USD -285.6 MM has Grown at -85.88%
ROCE(HY)
Lowest at -25.34%
DEBTORS TURNOVER RATIO(HY)
Lowest at 0 times
EPS(Q)
Lowest at USD -2.4
Here's what is working for CRISPR Therapeutics AG
Net Sales
At USD 1.76 MM has Grown at 72.09%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -248.29 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -49.84% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for CRISPR Therapeutics AG
EPS
Lowest at USD -2.4
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
